Athos Capital’s BeOne Medicines Ltd ONC Stock Holding History

Athos Capital’s Portfolio ONC Stock Details ONC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-2,114	Closed	-$575K	–	52
2025 Q1	$575K	Buy	+2,114	New	+$494K	0.68%	27

Other funds holding ONC

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Athos Capital's ONC Position: Q2 2025 in Review

Athos Capital sold out of BeOne Medicines Ltd (ONC) in Q2 2025, closing a stake of 2,114 shares — an estimated $575K sold.

Athos Capital first reported a position in ONC in Q1 2025 and held it in 1 quarter. The position peaked at $575K in Q1 2025. 243 funds tracked by Wall St. Rank hold ONC as of Q2 2025.

Athos Capital reported no remaining BeOne Medicines Ltd position as of Q2 2025 after selling out during the quarter.
Athos Capital sold 2,114 BeOne Medicines Ltd shares in Q2 2025, an estimated $575K.
Athos Capital first reported a position in BeOne Medicines Ltd in Q1 2025 and held it in 1 quarter.
Athos Capital's BeOne Medicines Ltd position peaked at $575K in Q1 2025.
243 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q2 2025.

Based on Athos Capital's 13F filing for Q2 2025, filed 14 Aug 2025.